Nektar Therapeutics
NKTR
NASDAQ·Healthcare·Biotechnology·Mkt cap $2.1B
$74.19
▼ -2.85%
P/E
-25.06
Mkt Cap
$2.1B
52-Wk Range
$33.40–$109.00
52-Week Range
$33.40 - $109.00
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 67.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Average volatility.
Growth
Strong growth ahead
Value
Deep value opportunity - significant discount to sector peers
Momentum
Hot
+31.0% over 3m
Quality
Excellent
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying NKTR right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 13, 2026
Reported EPS of -$1.23 vs -$1.97 consensus (+37.6% surprise). Revenue of $10.1M vs $10.4M expected (-2.8%).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+37.6%
Revenue trend · last 2Q
—
-9%
Q1 26
Q2 26
$10.9M
$10.1M
Margins · last 2Q
Profit
-401.0%
Wall Street consensus
5 analysts · 80% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
80%
Hold
20%
Sell
0%
Median Price Target
—
Latest: Wedbush · $80.00 · May 11, 2026
vs Industry
How NKTR stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.